M&A Stokes Red-Hot Life Sciences IPO Market

Loeb & Loeb partner Fran Stoller was quoted on the surge of IPO activity in the life sciences sector.  “One key factor fanning both stock prices and a robust M&A environment is the innovative technology being developed by clinical stage companies, showing promise of cracking the code on a cure for cancer and other diseases impacting vast numbers of people,” explained Stoller.  "People are very excited about these potential new treatments and new technologies for cancer and other diseases, like immunotherapy and gene therapy," she said. "There are good earnings, a lot of M&A activity and a lot of excitement about possible cancer treatments and the promises of other technologies. And then more companies manage to ride those tailwinds."

Click here to read the article.